Abstract
Modulation of 5-fluorouracil (FUra) using leucovorin (LV) is a standard treatment approach in patients with metastatic colorectal cancer. Modulation of FUra with interferon alfa has also shown some promise. Laboratory data have demonstrated increased cytotoxicity when FUra is combined with both LV and interferon. The current study examined the effects of double modulation of FUra using LV and interferon. Patients with measurable advanced colorectal cancer received bolus FUra 375 mg/m2 plus LV 20 mg/m2 daily for 5 days, repeated every 28 days. Recombinant human interferon alfa-2a, 3 million IU/m2 subcutaneously, was given daily on the days of chemotherapy then three times weekly. There was one complete response and nine partial responses (10/41) seen for an overall response rate of 24% (95% CI 12.0–40.0%). Overall, 70% of patients experienced one or more episodes of nonhematologic toxicity of grade 3 or more. Weight loss was common, with a mean decrease of 2.9 kg over the first two months (P<0.0001). Improvements in tumor-related symptoms were balanced by increased fatigue and a deterioration in body weight and performance status. There was no evidence of progressive changes in FUra metabolism from interferon usage.
Similar content being viewed by others
References
Advanced colorectal cancer meta-analysis project (1992) Modulation of FUra by leucovorin in patients with metastatic colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896–903
Bruckner HW, Motwanti BT (1991) Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 18: 443–461
Bukowski RM, Inoshita G, Yalavarthi P, et al (1992) A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma. Cancer 69: 889–892
Burkputt AR, Boyd MR (1980) Measurement of 5-fluorouracil in plasma by HPLC. Ann Biochem 106: 432–437
Cascinu S, Fedeli A, Fedeli SL, et al (1992) Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. Ann Oncol 3: 489–491
Chu E, Koeller DM, Johnston PG, Zinn S, Allegra C (1993) Regulation of thymidylate synthase in human colon cancer cells treated with FUra and interferon gamma. Mol Pharmacol 43: 527–533
Danhauser LL, Freimann JH Jr, Gilchrist TL, Gutterman JU, Hunter CY, Yeomans AC, Markowitz AB (1993) Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 11: 751–761
Erlichman C, Fine S, Wong A, Elkahim T (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 3: 469–475
Grem JL, Jordon E, Robson ME, et al (1993) Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 11: 1737–1745
Houghton JA, Adkins DA, Rahman A, Houghton PJ (1991) Interaction between 5-fluorouracil, [6RS] leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells. Cancer Commun 3: 225–231
Houghton JA, Morton CL, Adkins DA, Rahman A (1993) Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. Cancer Res 53: 4243–4250
Kemeny N, Younes A (1992) Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: The Memorial Sloan-Kettering Experience. Semin Oncol 19: 180–184
Kocha W and the CORFU-A collaborative group (1993) FUra plus interferon versus FUra plus LV in metastatic colorectal cancer-results of a multicentre, multinational phase III study. Proc Am Soc Clin Oncol 12: 562
Labianca R, Pacera G, Tedeschi L, Dallavalle G, Luporini A, Luporini G (1992) High dose alpha-2b interferon + folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavourable cost/benefit ratio. Tumori 78: 32–34
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 204–214
Moore MJ, Kaizer L, Erlichman C, Fine S (1991) A phase I clinical and pharmacologic study of 5-fluorouracil, leucovorin and interferon. Proc Am Soc Clin Oncol 10: 313
O'Connell MJ (1989) A phase III trial of FUra and leucovorin in the treatment of advanced colorectal cancer. Cancer 63: 1026–1030
Pazdur R, Ajani JA, Patt YZ, Gomez J, Bready B, Levin B (1993) Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer 71: 1214–1218
Pittman K, Perren T, Ward U, Primrose J, Slevin M, Patel N, Selby P (1993) Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. Ann Oncol 4: 515–516
Punt CJ, Burghouts JT, Croles JJ, Liessum PA van, deMulder PHM, Kamm Y (1993) Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study. Cancer 72: 2107–2111
Silgals RM, Ahlgen JD, Neefe JR, Rothman J, Rudnick S, Galicki FP, et al (1984) A phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer. Cancer 54: 2257–2261
Sobrero A, Nobile MT, Guglielmi A, et al (1992) Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer. Eur J Cancer 28A: 850–852
Sparano JA, Wadler S, Diasio RB, Zhang R, Lu Z, Schwartz EL, Einzig A, Wiernik PH (1993) Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 11: 1609–1617
Wadler S, Goldman M, Lyver A, Wiernik P (1990) Phase I trial of 5-fluorouracil and recombinant alpha-2a interferon in patients with advanced colorectal cancer. Cancer Res 50: 2056–2059
Weh HJ, Platz D, Braumann D, et al (1992) Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal cancer. Eur J Cancer 28A: 1820–1823
Author information
Authors and Affiliations
Additional information
This work was supported in part by a grant from Hoffman LaRoche Canada
Rights and permissions
About this article
Cite this article
Moore, M.J., Kaizer, L., Erlichman, C. et al. A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal caner. Cancer Chemother. Pharmacol. 37, 86–90 (1995). https://doi.org/10.1007/BF00685633
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685633